Abstract
Objective LINC01320 is a new oncogenic gene. Nevertheless, the effect of LINC01320 on pancreatic cancer (PC) is still unclear. This research aimed to seek the influence of LINC01320 on PC and its possible mechanism. Methods RT-qPCR is used to test the LINC01320 in tissues and cells. Cell viability, apoptosis, migration, and invasiveness are detected to explore the role of LINC01320 in PC, and target genes are predicted by bioinformatics methods. The mechanism of action was further explored by transfection of specific siRNA, miRNA mimetics, or miRNA inhibitors. In order to verify the effect of LINC01320 in vivo, we carried out tumor xenotransplantation. Results We conclude that LINC01320 is highly expressed in PC tissues and cell strains. LINC01320 high expression was bound up with a poor prognosis. LINC01320 gene knockout inhibited the growth, migration, and invasiveness of PC cells. In addition, LINC01320 is expressed by miR-324-3p, which is also supported by in vivo experiments. Conclusion LINC01320 is highly expressed in PC, and it can suppress the growth and migration of PC cells through targeted regulation of miR-324-3p, which is expected to become a latent target for clinical treatment.
Highlights
pancreatic cancer (PC), as the malignant tumor with the lowest survival rate in the digestive system, has the characteristics of invasive local infiltration and metastatic spread. erefore, these characteristics result in an overall median survival time of
In order to confirm the LINC01320 in PC, we analyzed the LINC01320 in GSE86436 chip. rough analysis, we found that LINC01320 expression increased in PC samples
We confirmed, for the first time, that LINC01320 was highly expressed in PC, and the prognosis of patients with high expression was poor
Summary
PC, as the malignant tumor with the lowest survival rate in the digestive system, has the characteristics of invasive local infiltration and metastatic spread. erefore, these characteristics result in an overall median survival time of
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
